UNSPSC 51311605: Efletirizine dihydrochloride

This classification denotes a histamine-1 receptor antagonist C21H24F2N2O3.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JQ7ZT5MRA0, chemically known as (2-(4-bis(p-fluorophenyl)methyl)-1-piperazinyl)ethoxy)acetic acid, dihydrochloride, but more generally known as efletirizine dihydrochloride, which bears US NIH Compound Identifier 156659. Most nations, for tariff and trade purposes, schedule efletirizine dihydrochloride under HS 29335995 and SITC 51576.

As of Q4 2014, EFLETIRIZINE DIHYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Efletirizine dihydrochloride bears US NLM identifiers UMLS ID C2348383 and NCI Concept Code C72751. SMILES: C1CC(CCC1C(C2CCC(CC2)F)N3CCN(CC3)CCOCC(=O)O)F.CL.CL.

UNSPSC 51311605 Efletirizine dihydrochloride is a Commodity code that nominally covers a specific pharmaceutical compound, but recent state and local solicitations under this code do not focus on efletirizine itself; instead, they reflect broader pharmaceutical procurement activity including naloxone, generic multi-source pharmaceuticals, over-the-counter products, and direct-to-manufacturer prescription programs. State and local governments soliciting under this code span county health departments, state health agencies, and cooperative purchasing alliances serving multiple jurisdictions. Seminole County, Florida issued an IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, while the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP to establish contracts for generic pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon. The Texas Health and Human Services Commission issued a Request for Information exploring direct-to-manufacturer prescription fulfillment models outside traditional pharmacy benefit manager arrangements, signaling interest in alternative pharmaceutical supply-chain structures.

Recent activity concentrates in Minnesota, Florida, and Texas. The MMCAP RFP (due March 26, 2026) requires vendors to supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—with pricing weighted 75 percent in evaluation, compliance and administrative requirements accounting for 15 percent, and contract terms (fixed pricing and EDI capability) 10 percent; vendors must certify current Good Manufacturing Practices compliance and Drug Supply Chain Security Act adherence, maintain relationships with at least two of the three wholesalers, and carry commercial general liability insurance of $5,000,000 per occurrence. The Seminole County IFB (due July 26, 2023) requires E-Verify compliance, drug-free workplace certification, and a three-month probationary termination clause, with potential FEMA funding introducing federal compliance obligations. No explicit set-aside designations appear across these solicitations; however, vendors should anticipate performance penalties ranging from $200 to $1,500 per violation and administrative fees (3 percent under MMCAP) levied against contract purchases.